BusinessImmuron Limited Issues Correction to Misleading Halt Announcement HeadlineBy Nasdaq OMXMar 7, 2018, 10:06 PM UTC
BusinessNymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line EfficacyBy Nasdaq OMXNov 29, 2016, 2:45 PM UTC
